Press Release
RSS/Syndication
SearchUS nod to four Zydus Cadilla drugs
The US Food and Drug Administration has granted approval to four drugs manufactured by the Gujarat-based pharmaceutical Zydus Cadilla.
- Chembond starts up new plant in Gujarat
- BCCL picks up stake in Manhattan Communications Private Limited
- Venture Infotek takes the lead in Re-Defining Disaster Management
- Bank of Rajasthan revises NRE & FCNR rates
- A historic first, India enters the World Schools Debating Championships
The US Food and Drug Administration has granted approval to four drugs manufactured by the Gujarat-based pharmaceutical Zydus Cadilla.
Announcing this Thursday, the company said authorities in the US had given the green signal to its fats-lowering agents and tentative approval to an anti-depressant, anti-hypertensive drug as well as a hormonal drug administered in the treatment of breast cancer.
The company said while anti-depressant Escitalopram Oxalate tablets had an annual sales turnover of $3 billion in 2007, the LDL cholesterol lowering drug Pravastain Sodium tablets, according to USFDA's National Drug Code directory (NDC), has $1.9 billion American market.
The company quoted NDC to say that the hormonal therapy drug Anastrazole has an estimated market of $13 million and the anti-hypertensive Losartan Potassium and Hydrochlorthiazide had approximate sales touching $785 million last year.
Copyright © India PRwire/Indo Asian News Service. Reproduction of news articles or any other content in whole or in part in any form or medium without express written permission of India PRwire is prohibited.